Development of a novel tyrosine kinase 2 inhibitor ARTS-011 and its first-in-human single and multiple ascending dose Phase I study to evaluate the tolerability, safety, pharmacokinetic profile and food effects.

Key Points

• The central aim is to evaluate the safety, tolerability, and pharmacokinetic profile of ARTS-011 in human subjects.
• Conducted a Phase I clinical trial
• Administered single and multiple ascending doses of ARTS-011
• Monitored safety and tolerability outcomes
• Assessed pharmacokinetics and food effects
• ARTS-011 demonstrated an acceptable safety profile.
• Results indicate potential for once-daily dosing in patients.
• Findings support further development in inflammatory and autoimmune diseases.